BASEL, Switzerland – 15th March 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new [...]
8th March 2023 – We are glad to announce the following promotions of our team members: Loredana Siani to Vice President of Technical and CMC Development, Tiffany Brooke Muller to Senior [...]
1st March 2023 -We are thrilled to welcome Sarah Runswick as Senior Director of Clinical Science at Nouscom. Sarah is an experienced global clinical scientist with over 20 years expertise in [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
